EMA Begins Review of COVID-19 Treatment
The agency is reviewing data on the use of molnupiravir (MK 4482 or Lagevrio) for potential use to treat COVID-19 prior to authorization.
The European Medicines Agency announced on Nov. 8, 2021 that it will be reviewing data available on the use of molnupiravir (MK 4482 or Lagevrio) as a treatment for COVID-19 prior to authorization. A rolling review of the drug is currently ongoing. The agency’s Committee for Medicinal Products for Human Use (CHMP) will provide recommendations to national authorities in the European Union regarding the possibly early use of the medication. The decision came because of the rise in infections across the EU.
“EMA and HMA [Heads of Medicines Agencies] remain committed to expediting the evaluation of much needed COVID-19 treatments and vaccines, while ensuring these meet the EU’s high standards of safety and efficacy. EMA will communicate on the outcome of this review and that of the rolling review once they conclude,” the agency stated in a press release.
Molnupiravir, an oral antiviral medicine that reduces the ability of SARS-CoV-2 to multiply in the body, was developed by Merck Sharp & Dohme in collaboration with Ridgeback Biotherapeutics.
Source: EMA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
